Biotech Specialty Pharma

Aduro Biotech

626 Bancroft Way, 3C
Berkeley, CA 94710-2224 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Non-invasive targeted therapeutics for the treatment of cancers.

Management Stephen T. Isaacs is Chairman and CEO of Aduro. Prior to Aduro, Mr. Isaacs was founder, President and CEO of Cerus Corporation (NASD:CERS), and grew Cerus from three employees to over two hundred and fifty, took Cerus public and developed two marketed products. Prior to Cerus, Mr. Isaacs held a non-teaching faculty position at the Department of Chemistry at UC Berkeley, where he published over 20 articles and 40 patents. Mr. Isaacs holds a BA degree in Biochemistry from the University of California at Berkeley. Seth David Model is acting CFO of Aduro. He came to Aduro from Triton BioSystems, one of the two companies that merged to form Aduro in 2008, where he was also CFO and a founder of the company. Mr. Model???s prior experience includes ImageMax, Inc., (now DataBank IMX), where he was a founder and President, and part of the group that took ImageMax public in 1997. Prior to that, Mr. Model co-managed Airfoil Technologies, LLC, a joint venture between Teleflex and General Electric to provide the world's commercial airlines with turbine repair services. (General Electric acquired 100% of the venture in 2009.) Mr. Model began his career as a mechanical engineer with Pratt and Whitney Aircraft, designing engine components and later running development and test programs. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Yale University. Dirk G. Brockstedt is Vice President of Research and Development, and has more than 15 years of experience in the fields of immunology and oncology originating with his PhD from Stanford University. He was the third employee in the original Vaccine group at Cerus Corporation and later brought the technology to Aduro. He was instrumental in the development of both the live-attenuated and killed Listeria strains, and he led the development of the lead product, CRS-207. Prior to Cerus Corporation, Dr. Brockstedt spent 4 years at Aventis in the Immunotherapy and Anti-Angiogenesis group developing novel therapies against cancer. Dr. Brockstedt is the author of more than 20 peer-reviewed scientific articles and is a named inventor on 5 issued patents and several patent applications. Aimee Murphy is the Director of Clinical Operations. She has more than 12 years of experience in all phases of clinical research and trial management, with a focus on therapeutic and prophylactic vaccines for cancer and infectious diseases. While at Cerus Corporation and Anza Therapeutics, she managed the first Phase 1 studies for what are now Aduro's therapeutic vaccines. Prior to working with Aduro???s platform, she worked at VaxGen for 6 years on the world's first Phase 3 prophylactic vaccine trials for HIV-1 as well as vaccine trials for anthrax and smallpox. Prior to working in clinical development, Ms. Murphy worked in Quality Assurance at Bayer Pharmaceuticals. She holds a BS in Biology from Pepperdine University.

Click here for Financial Data
Keywords: cancer, breast, head, neck, lung, colon, ovarian, pancreatic, Urology, prostate, urinary, bladder, erectile, tumor, antibody, magnetic field energy, non-materials, Oncology

Comment


Updated: Mar. 28, 2018


Description

After completing extensive research in immunotherapy, Listeria monocytogenes was chosen, which has been used as a research tool for more than 50 years because of its ability to induce potent cellular......view more

Products / Services

Listeria......view more

Technology / Differentiation

For more than 50 years, immunologists have used Listeria as a research tool to study the mammalian immune system. Now Aduro BioTech is engineering Listeria to treat cancer and infectious diseases. ...view more

Revenue / Funding

April 20, 2011 Aduro BioTech completes $19.25 million Series B financing....view more

Status

April 18, 2011 Aduro BioTech licenses GVAX Pancreas from BioSante Pharmaceuticals. December 7, 2010 Aduro BioTech announces first presentation of clinical results from CRS-207 Phase 1 trial. No...view more

RELATED COMPANIES



0000-00-00-5559